There are currently 842 clinical trials in Jacksonville, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Florida, Mayo Clinic - Jacksonville, Mayo Clinic and Mayo Clinic Florida. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
07/17/2025
Locations: East Coast Institute for Research, LLC, Jacksonville, Florida
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Register for Updates
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
NCT06676579
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: IgA Nephropathy (IgAN)
Register for Updates
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574
Recruiting
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/17/2025
Locations: UF Health Jacksonville, Jacksonville, Florida
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction
Register for Updates
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
NCT04040205
Recruiting
This is a single-arm, phase II study that will enroll a total of 45 subjects. All subjects will have a confirmed diagnosis of metastatic or unresectable soft tissue sarcoma or bone sarcoma. All subjects must have intact Rb, identified at the time of screening, by immunohistochemistry testing of submitted tumor specimen. Subjects will receive Abemaciclib 200 mg twice daily until progression or discontinuation criteria are met.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Chondrosarcoma, Osteosarcoma, Soft Tissue Sarcoma
Register for Updates
Observational, Non-Interventional Study Supporting Validation of VO2Max Estimation Methods Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)
NCT05678530
Recruiting
In this study, the hypothesis being explored is that VO2Max and other CPET parameters can be accurately estimated from biosignals (namely, motion from accelerometers and cardiopulmonary variables from EKG) collected during activities of daily living using wearable biosensors worn by study participants. This study will aim to collect development and validation data for a machine learning algorithm and to evaluate the performance of the algorithm. A total of 300 participants will be enrolled inclu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Cardiopulmonary
Register for Updates
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors
NCT05932862
Recruiting
This is a FIH, multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as PK and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Exelixis Clinical Site #15, Jacksonville, Florida
Conditions: Advanced Solid Tumor
Register for Updates
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337
Recruiting
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Research Site 1154-0, Jacksonville, Florida
Conditions: Metastatic Breast Cancer
Register for Updates
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805
Recruiting
This study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also consider feedback from patients on their experience with this treatment.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/16/2025
Locations: GSK Investigational Site, Jacksonville, Florida
Conditions: HIV Infections
Register for Updates
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
NCT06704191
Recruiting
This phase Ib/II trial compares the safety, tolerability and acceptability of intravesical chemotherapy given at home to in-clinic administration in patients with non-muscle invasive bladder cancer. Chemotherapy drugs, such as bacillus Calmette-Guerin (BCG), gemcitabine, docetaxel, and mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Standard of care chemotherapy for non-invasiv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Non-Muscle Invasive Bladder Carcinoma, Stage I Bladder Cancer AJCC V8, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Register for Updates
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
NCT06836063
Recruiting
The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/16/2025
Locations: Clinical Neuroscience Solutions, Inc., Jacksonville, Florida
Conditions: Major Depressive Disorder (MDD)
Register for Updates
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
NCT06899217
Recruiting
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with idiopathic gastroparesis compared to a placebo * To evaluate the safety of CIN-102 when given to patients with idiopathic gastroparesis compared to a placebo Partic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: ENCORE Borland Groover Clinical Research, Jacksonville, Florida
Conditions: Idiopathic Gastroparesis
Register for Updates
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988
Recruiting
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/15/2025
Locations: Florida Retina Institute - Jacksonville, Jacksonville, Florida
Conditions: Macular Neovascularization Secondary to Age-Related Macular Degeneration
Register for Updates